New TB vaccine granted orphan drug status.

New TB vaccine granted orphan drug status.

Détails bibliographiques
Auteurs principaux:	Lang, T, Hill, A, Mcshane, H, Shah, R, Towse, A, Pritchard, C, Garau, M
Format:	Journal article
Langue:	English
Publié:	2005

Documents similaires

Establishing a reasonable price for an orphan drug
par: Mikel Berdud, et autres
Publié: (2020-09-01)

Towards new TB vaccines
par: Brazier, B, et autres
Publié: (2020)

Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
par: Kalipso Chalkidou, et autres
Publié: (2020-04-01)

TB vaccines in clinical development
par: Ginsberg, A, et autres
Publié: (2016)

TB vaccines in clinical development
par: Ginsburg, A, et autres
Publié: (2016)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
par: Mcshane, H
Publié: (2008)

Need for more TB vaccine field sites.
par: Mcshane, H
Publié: (2009)

TB vaccines in clinical development
par: Ginsberg, AM, et autres
Publié: (2016)

Development of Orphan Vaccines: An Industry Perspective
par: Jean Lang, et autres
Publié: (1999-12-01)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
par: Whelan, K, et autres
Publié: (2009)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
par: Minassian, A, et autres
Publié: (2011)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
par: Owiafe, P, et autres
Publié: (2012)

TB vaccine development: where are we and why is it so difficult?
par: Wilkie, M, et autres
Publié: (2014)

Implementation status of pharmacological studies in the development of orphan drugs
par: Saki Yokoshiki, et autres
Publié: (2024-01-01)

Progress and challenges in TB vaccine development
par: Voss, G, et autres
Publié: (2018)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
par: Pathan, A, et autres
Publié: (2012)

NOW THE SOLUTION IS HERE – SOCIAL ASSISTANCE FOR ORPHANED CHILDREN: THE EXTENDED CHILD SUPPORT GRANT
par: Sipho Sibanda, et autres
Publié: (2023-04-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
par: Pathan, A, et autres
Publié: (2012)

A review of clinical models for the evaluation of human TB vaccines.
par: O'Shea, M, et autres
Publié: (2016)

Advances in orphan drug development: Time to change the status and stereotype
par: Sayanta Thakur
Publié: (2022-01-01)

Current status and trend of clinical development of orphan drugs in China
par: Ziling Xiang, et autres
Publié: (2022-07-01)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
par: Ewa Stawowczyk, et autres
Publié: (2019-11-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
par: Morrell, L, et autres
Publié: (2017)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
par: Kathryn T. Whelan, et autres
Publié: (2011-01-01)

Orphan drugs and rare diseases /
par: Pryde, David C., editor, et autres
Publié: (2014)

Donor investment choices in developing countries: a methodology and some illustrative results based on Public-Private partnerships for product development (PD PPPs)
par: Gray, A, et autres
Publié: (2007)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
par: Odutola, A, et autres
Publié: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
par: Odutola, A, et autres
Publié: (2012)

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
par: ZHANG Shan, et autres
Publié: (2023-04-01)

Mechanism of coordinated access to orphan drugs
par: DeRidder R, et autres
Publié: (2012-11-01)

International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea
par: Eun Young Shin, et autres
Publié: (2024-12-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
par: Liz Morrell, et autres
Publié: (2017-08-01)

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
par: Kathleen L. Miller, et autres
Publié: (2020-09-01)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.
par: McShane, H, et autres
Publié: (2014)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
par: McShane, H, et autres
Publié: (2014)

Rare diseases and orphan drugs.
par: Aronson, J
Publié: (2006)

Predictors of orphan drug approval
par: Heemstra Harald
Publié: (2010-10-01)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
par: Hans-Georg Eichler, et autres
Publié: (2023-01-01)

Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
par: Pejčić Ana V., et autres
Publié: (2016-01-01)

Adenylosuccinic Acid: An Orphan Drug with Untapped Potential
par: Emma Rybalka, et autres
Publié: (2023-05-01)